Breaking news in Daily Telegraph.....
Immutep lifts after Merck trial result
Trevor Chappell, Australian Associated Press
34 minutes ago
Immutep shares have jumped more than 16 per cent after global pharmaceutical giant Merck reported that a trial of its drug Keytruda had improved the overall survival rate of patients with non-small cell lung cancer.
Separately, Immutep and Merck are jointly evaluating the combination of Immutep's immunotherapy product, eftilagimod alpha, with Merck's Keytruda to treat lung, head and neck, and ovarian cancers.
Shares in Immutep were 0.4 cents, or 16.7 per cent, higher at 2.8 cents at 1207 AEST.
Originally published as Immutep lifts after Merck trial result
Slow & Steady, page-10
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
44.5¢ |
Change
-0.005(1.11%) |
Mkt cap ! $529.0M | |||
| Open | High | Low | Value | Volume |
| 45.0¢ | 45.5¢ | 43.5¢ | $873.8K | 1.958M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 13599 | 44.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 46.0¢ | 196504 | 8 |
View Market Depth
| Last trade - 16.10pm 15/05/2024 (20 minute delay) ? |
|
|||||
|
Last
45.0¢ |
Change
-0.005 ( 1.12 %) |
||||
| Open | High | Low | Volume | ||
| 44.5¢ | 45.5¢ | 44.0¢ | 350916 | ||
| Last updated 15.58pm 15/05/2024 ? | |||||
| IMM (ASX) Chart |